THE UNITED REPUBLIC OF TANZANIA

MINISTRY OF HEALTH

TANZANIA MEDICINES AND MEDICAL DEVICES AUTHORITY

PUBLIC ASSESSMENT REPORT FOR CELMAC 200 (CELECOXIB 200 MG) HARD GELATIN CAPSULES

Version number 1.0
21 August, 2023

TMDA Headquarters, Plot No. 56/1, Block E, Kisasa B Centre, Hombolo Road, P. O. Box 1253, Dodoma – Tanzania, Telephone: +255 (26) 2961989/2061990/+255 (22) 2450512/2450751/2452108, Email: info@tmda.og.tz, Website: **www.tmda.go.tz**

Toll free: 0800110084

1. Introduction

Celmac 200 hard gelatin capsules contains celecoxib as the active substance. Celecoxib is an oral, selective, cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range (200-400 mg daily). No statistically significant inhibition of COX-1 (assessed as ex vivo inhibition of thromboxane B2 [TxB2] formation) was observed in this dose range in healthy volunteers. Celmac 200 hard gelatin capsules is approved in Tanzania for use in adults only.

Product details

Registration number	TAN 23 HM 0258
Brand name	Celmac 200
Generic name, strength, and form	Each hard gelatin capsule contains: Celecoxib 200mg
ATC classification	M01AH01-antiinflammatory and antirheumatic products, non-steroids; Coxibs
Distribution category	POM
Country of origin	India
Associated product	Celmac 400
Marketing Authorization Holder	Ajanta Pharma Limited Ajanta House, Charkop, Kandivli (W), Mumbai 400067, India
Local Technical Representative	Astra Pharma (T) Ltd, Plot No. 12, Vinginguti Industrial Area, Nyerere Road, Opp: Pepsi Tanzania Ltd, Dar Es Salaam,

1.1 Assessment procedure

The application for registration of Celmac 200 capsules was submitted on 29/07/2021. The product underwent full assessment. Assessment was completed in 4 (four) rounds of evaluation and the product was registered on 01/06/2023.

1.2 Information for users

Visual description of the finished product	Violet (Cap)/ white (body) hard gelatin capsules of size '1', containing white to off white coloured powder.
Primary packing material	Alu/Alu Blister
Secondary packing materials	Printed carton box
Shelf-life and storage condition	24 months, Do not above 30°C. Protect from light and moisture.
Route of administration	Oral

Therapeutic indications	The products are Prescription-Only Medicines (POM), indicated in adults for the symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis

2. Labelling and product information

Summary of product characteristics
The SmPC included all the relevant information to ensure correct and safe use of the medicine by healthcare providers. The complete SmPC can be accessed here.

Package insert/leaflet
The package insert is confirmed to be derived from the SmPC and contains sufficient data for the end user. Since the product is POM, the package insert contains full prescribing information as per SmPC.

Container labels
The product label information is presented in English. Details in the secondary pack label include:
Brand name: Celmac 200

Composition: Each hard gelatin capsule contains: Celecoxib 200mg

Pack size: 30's tablets

Manufacturing details: batch number, manufacturing date, and expiry date

Storage conditions: Do not above 30°C. Protect from light and moisture.

Manufacturer address: physical address of release site

Unique identifier: Not applicable

Special warnings/precautions or instructions for use: N/A

The details of the primary pack include:

Brand name and strength: Celmac 200

Manufacturing details: batch number, manufacturing date and expiry date

Name of manufacturer: Ajanta Pharma Limited

The content of the primary and secondary labels was aligned to the requirements of the Part V of the Compendium: Guidelines on Format and Content of Product Labels for Medicinal products. The label contains sufficient information for proper identification of the medicine and post marketing follow up of the product.

Mock labels are appended as annex I.

3. Scientific discussion

Quality of Active Pharmaceutical Ingredient

Information on the quality of the API was submitted in form of DMF.

General Information

Celecoxib API is compendia in USP, Ph.Eur., and BP.

Molecular formula: $C_{17}H_{14}F_3N_3O_2S$

Chemical name:

(4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl] benzenes fonamide.

Structure:



General properties

Celecoxib is a white or almost white crystalline powder, which is practically insoluble in water, freely soluble to soluble in anhydrous ethanol and soluble in methylene chloride. The crystalline form of celecoxib used corresponds to Form III.

Manufacture

Celecoxib API manufacturer is Aarti Drugs Limited, Plot No. W 71(B) and 72 (B), M.I.D.C., Tarapur,Tal. - Palghar Dist.: Thane - 401 506, Maharashtra. India. The manufacturing complies with GMP requirements as evidenced by the submitted GMP certificate. Celecoxib API is manufactured by chemical synthesis using conventional techniques. Sufficient controls of quality of materials and in-process checks were employed throughout the manufacturing process.

Specifications

Specifications

The API specifications were set as per USP, in-house standards and ICHQ3A. The parameters monitored during quality control are: description, solubility, identification by HPLC and IR, heavy metal, residue on ignition, related substances, water content, assay, residual solvents, and particle size. Compliance to these specifications were established via batch analysis data and stability studies.

Stability and container closure system

The shelf-life period of Celecoxib API is 60 months when packed in food grade double polythene bags (Inner transparent and outer black) which is then packed in fibre drums and stored in tight containers, protected from light and moisture, store at room temperature

Quality of the Finished Pharmaceutical Product

Formulation

Celmac 200 is a violet (Cap)/ white (body) hard gelatin capsules of size '1', containing white to off white coloured powder.

Celmac 200 contains the Celecoxib and other ingredients listed here after: lactose monohydrate, sodium lauryl sulphate, croscarmellose sodium, povidone, purified water, magnesium stearate, and empty hard gelatin capsules '1' yellow/ white. The quantities of all ingredients are confirmed to be in line with the recommendations of Handbook of Pharmaceutical Excipients, 8th Edition in terms of function and quantities.

Manufacture

The finished product manufacturer is Ajanta Pharma Limited, B-4-5-6, MIDC Industrial Area, Paithan, Aurangabad, 431148, Dist: Aurangabad, Maharashtra, India. The compliance of the sites to TMDA GMP standards was confirmed through site inspection on DD/MM/YYYY.

Specifications

The FPP is compendia. The manufacturer controls the quality of the finished product as per USP standards and ICH requirements. The parameters monitored during quality control are: description, identification of the API (HPLC, TLC), average weight of filled capsules, average filled net content of capsules, disintegration, loss on drying, uniformity of dosage units (by weight variation), dissolution (HPLC detection), degradation products (HPLC), assay (HPLC), and microbiological examination of non-sterile products. Compliance to the standard was established using batch analysis data and stability data.

Stability and container closure system

Stability studies were conducted on 3(three) batches of the finished product stored at 30 ± 2°C & RH: 75 ± 5% RH for 24 months and 40± 2°C & RH: 75% ± 5% RH for 6 months. Based on the

stability data presented, the approved shelf-life is 24 months when stored in Alu / Alu blister with storage condition ‘Do not store above 30°C. Protect from light and moisture’.

Safety and efficacy information

The biowaiver was approved based on additional strength.

Celmac 200 fulfilled the criteria for waiving an in-vivo bioequivalence study as per relevant TMDA guidance. Dissolution profiles of Celmac 200 (Celecoxib 200mg)) capsules was compared to Celmac 200 (Celecoxib 200mg)) capsules. Less than 85% of the labelled amount of Celecoxib had dissolved after 15 minutes in some media. As less in some media less than 85% is dissolved within 15 minutes. Therefore, necessitating calculation of similarity factor f2, which was noted to be above 50.

4. Benefit-Risk Assessment and Conclusion

On basis of the data submitted, the current state of knowledge and compliance to Good Manufacturing Practice, the benefit of the product outweighs the risks associated with its use when used in accordance to the summary of product characteristics. Celmac 200 (Celecoxib 200mg)) capsules is recommended for registration.

5. Post-approval updates

Variation applications

Reference number	Date submitted	Change requested	Recommendation	Granting date

Feedback from pharmacovigilance, post marketing surveillance and enforcement activities

Type of feedback	Impact	Response

Re-registration applications

Application for renewal of registration was submitted on <DDMMYYYY>. The application was finalized in <number> rounds of evaluation. The product was confirmed to still be compliant to

the standards of quality, safety and efficacy, hence registration was renewed on <DDMMYYYY>.

PART 5: CHANGE HISTORY

Version number	Date	Description of update	Section(s) Modified	Approval date

Annex I: Mock up labels;

Primary pack label;

Secondary pack label: